Physician profile
Cory Fielding
NPI 1154689040
$13,755.88
in general payments reported to CMS, 2019-2025
37 companies · $2,498 in 2025
The $2,498 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,607 · 2020: $1,427 · 2021: $1,848 · 2022: $1,688 · 2023: $2,038 · 2024: $2,649 · 2025: $2,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,185.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,891.46 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,112.71 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $971.10 | 2019-2025 | |
| Janssen Biotech, INC. | $899.05 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $779.39 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $426.57 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $400.47 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $395.87 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $294.32 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $290.48 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $268.39 | 2019-2025 | Ocaliva |
| Pfizer INC. | $210.25 | 2019-2025 | |
| Lilly USA, LLC | $200.91 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $187.59 | 2020-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $182.38 | 2024-2025 | Voquezna |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $178.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $158.32 | 2019-2025 | Injectafer |
| Celgene Corporation | $139.83 | 2021-2023 | Zeposia |
| Ucb, INC. | $113.97 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $79.56 | 2019-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $73.41 | 2023 | |
| Organon LLC | $70.59 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $66.75 | 2024 | |
| Amag Pharmaceuticals, INC. | $65.37 | 2019-2020 | |
| Shionogi INC | $45.48 | 2019 | |
| Redhill Biopharma INC. | $40.91 | 2021 | |
| Braintree Laboratories, INC. | $32.79 | 2019-2025 | Suflave |
| Allergan, INC. | $29.03 | 2019 | |
| Dynavax Technologies Corporation | $28.98 | 2022 | |
| Evoke Pharma, INC. | $24.07 | 2023 | Gimoti |
| Alfasigma USA, INC. | $16.48 | 2021 | |
| Shire North American Group INC | $14.52 | 2019 | |
| Amgen INC. | $14.19 | 2023 | Amjevita, Avsola |
| Astrazeneca Pharmaceuticals LP | $13.97 | 2023 | Andexxa |
| Ipsen Biopharmaceuticals, INC | $13.46 | 2025 | Iqirvo |
| Masimo Corporation | $12.53 | 2021 | |
| Medtronic, INC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Fielding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.